What development phase is Syncurine in?

Syncurine is FDA-approved (marketed).

What is the generic name of Syncurine?

DECAMETHONIUM is the generic (nonproprietary) name of Syncurine.

Last reviewed 2026-04-20 · How we verify

Syncurine (DECAMETHONIUM)

FDA-approved approved Small molecule Quality 15/100

Syncurine (DECAMETHONIUM) is a small molecule drug that targets the muscarinic acetylcholine receptor M2. Originally developed, it is currently off-patent and has no active Orange Book patents. It was FDA approved in 1975 for certain indications. However, due to lack of information on its pharmacokinetics, its commercial status is limited. As an off-patent drug, it may be available from generic manufacturers.

At a glance

Generic name	DECAMETHONIUM
Drug class	decamethonium
Target	Acetylcholinesterase, Histamine H3 receptor, Muscarinic acetylcholine receptor M2
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved
First approval	1975

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Syncurine CI brief — competitive landscape report
Syncurine updates RSS · CI watch RSS